Cantor Fitzgerald Has Negative View of CRBU FY2025 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Caribou Biosciences in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will earn ($1.85) per share for the year, down from their prior forecast of ($1.31). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The business had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $9.33.

Caribou Biosciences Stock Down 4.3%

Shares of NASDAQ CRBU opened at $0.78 on Wednesday. The business has a fifty day simple moving average of $0.88 and a two-hundred day simple moving average of $1.44. The firm has a market cap of $72.80 million, a PE ratio of -0.47 and a beta of 2.36. Caribou Biosciences has a twelve month low of $0.66 and a twelve month high of $3.91.

Institutional Trading of Caribou Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Aberdeen Group plc boosted its stake in Caribou Biosciences by 126.5% in the 1st quarter. Aberdeen Group plc now owns 411,144 shares of the company’s stock worth $375,000 after purchasing an additional 229,657 shares in the last quarter. Nuveen LLC purchased a new stake in Caribou Biosciences in the 1st quarter worth approximately $302,000. Nelson Capital Management LLC grew its position in Caribou Biosciences by 31.1% during the first quarter. Nelson Capital Management LLC now owns 85,020 shares of the company’s stock valued at $78,000 after buying an additional 20,162 shares during the period. Cerity Partners LLC grew its position in shares of Caribou Biosciences by 163.6% during the 1st quarter. Cerity Partners LLC now owns 40,722 shares of the company’s stock valued at $37,000 after acquiring an additional 25,271 shares during the period. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Caribou Biosciences in the first quarter valued at approximately $559,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.